Prostate cancer expression

Most steroid-sensitive cancers express specific cell surface receptors. Prednisone-sensitive lymphomas, estrogen-sensitive breast cancers, and prostatic cancers express specific receptors for corticosteroids, estrogens, and androgens, respectively. It is now possible to assay tumor specimens for steroid receptor content and to identify which individual patients are likely to benefit from hormonal therapy. Measurement of the estrogen receptor (ER) and progesterone receptor (PR) proteins in breast cancer tissue is now standard clinical practice. ER or PR positivity predicts response to hormonal therapy, whereas patients whose tumors are ER-negative generally fail to respond to such treatment. 

TRPV5 and TRPV6, also known as the epithelial Ca2+ channel or ECaC (TRPV5) and Ca2+transporter 1 or Ca2+ transporter-like (TRPV6), are the only two Ca2+-selective TRP channels identified so far. They may function in vitamin D-dependent transcellular transport of Ca2+in kidney, intestine and placenta. TRPV6 is also expressed in pancreatic acinar cells, and in prostate cancer, but not in healthy prostate or in benign prostate hyperplasia. 

Li Y, Hong X, Hussain M, Sarkar SH, Li R, Sarkar FH. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol Cancer Ther 2005 4 389-98. 

HABERMANN H, RAY V, HABERMANN w and PRiNS G s (2001) Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer. J Urol 166(6) 2267-72. 

Schwarze SR, Luo J, Isaacs WB, Jarrard DF. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 2005 13 13. 

Androgen independence is a common feature of prostate cancer progression. CXCR1 expression and the emergence of androgen independence were examined in prostate cancer specimens from patients undergoing hormonal treatment... 

Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006 66 124-134. 

Murphy C, McGurk M, Pettigrew J, et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 2005 11 4117-4127. 

Huang J, Yao JL, Zhang L, et al. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 2005 166 1807-1815. 

Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW Jr. Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res 2004 10 8743-8750. 

Forbes, K, K Gillette, and I Sehgal. 2003. Lycopene increases urokinase receptor and fails to inhibit growth or connexin expression in a metastatically passaged prostate cancer cell line a brief communication. Exp Biol Med 228 967-971. 

Gitenay, D, B Lyan, J Talvas, A Mazur, S George, C Caris-Veyrat, and E Rock. 2007. Serum from rats fed red or yellow tomatoes induced Connexin-43 expression independently from lycopene in a prostate cancer cell line. Biochem Biophys Res Commun 364 578-582. 

Lin, X, M Tascilar, WH Lee et al. 2001. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 159 1815-1826. 

Ryan, CJ, CM Haqq, J Simko et al. 2007. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol 2007(2) 134—140. 

Xing, N, Y Chen, SH Mitchell, and CYF Young. 2001. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis 22(3) 409 414. 

---